Otsuka Announces Plans to Buy Avanir for $3.5 Billion
Japanese drugmaker Otsuka announced plans to buy CNS-specialist Avanir Pharmaceuticals for $3.5 billion in an all-cash tender offer.
Otsuka Pharmaceutical announced on Dec. 2, 2014 that it had reached an agreement in which Otsuka America, its US subsidiary, would acquire Avanir Pharmaceuticals for $3.5 billion. Avanir, a biopharmaceutical company specializing in central nervous system (CNS) diseases, is the US-based manufacturer of Nuedexta, the only FDA-approved treatment for the neurological disease pseudobulbar affect (PBA). PBA is a neurological disease characterized by sudden and uncontrollable laughing or crying, secondary to a neurological condition such as traumatic brain injury, multiple sclerosis, Parkinson’s, a stroke, or Alzheimer’s disease
Under the agreement, Otsuka will obtain rights to Nuedexta, as well as AVP-786, a late-stage investigational compound developed to treat agitation associated with Alzheimer’s.
Source: Otsuka
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
